Neuraminidase Inhibitors - Pipeline Insights, 2017

  • ID: 4037048
  • Drug Pipelines
  • 60 pages
  • DelveInsight
1 of 3
“Neuraminidase Inhibitors - Pipeline Insights, 2017” provides in depth insights on the pipeline drugs and their development activities around the Neuraminidase Inhibitors. The This report covers the product profiles in various stages of development including Discovery, Pre - clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. This report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Neuraminidase Inhibitors. This report also assesses the Neuraminidase Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please Note: This report requires certain updates. We have all the information available but require 2 business days to complete the process and ensure it is as up - to - date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope:
  • The report provides competitive pipeline landscape of Neuraminidase Inhibitors
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Neuraminidase Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Neuraminidase Inhibitors and also provide company profiling
  • The report also gives the information of dormant and discontinued pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
Delivery Time: 2 Working Days.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
Neuraminidase Inhibitors Overview
Neuraminidase Inhibitors Disease Associated
Neuraminidase Inhibitors Pipeline Therapeutics
Neuraminidase Inhibitors Therapeutics under Development by Companies
Neuraminidase Inhibitors Filed and Phase III Products
Comparative Analysis
Neuraminidase Inhibitors Phase II Products
Comparative Analysis
Neuraminidase Inhibitors Phase I and IND Filed Products
Comparative Analysis
Neuraminidase Inhibitors Discovery and Pre-Clinical Stage Products
Comparative Analysis
Drug Candidate Profiles
Neuraminidase Inhibitors - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Neuraminidase Inhibitors - Discontinued Products
Neuraminidase Inhibitors - Dormant Products
Companies Involved in Therapeutics Development for Neuraminidase Inhibitors
Appendix
Methodology
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Neuraminidase Inhibitors by Therapy Area, 2017
Number of Products under Development for Neuraminidase Inhibitors, 2017
Number of Products under Development by Companies
Comparative Analysis by Filed and Phase III Products, 2017
Comparative Analysis Phase II Products, 2017
Comparative Analysis Phase I and IND Filed Products, 2017
Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
Drug Candidates Profiles
Neuraminidase Inhibitors Assessment by Monotherapy Products
Neuraminidase Inhibitors Assessment by Combination Products
Neuraminidase Inhibitors Assessment by Route of Administration
Neuraminidase Inhibitors Assessment by Stage and Route of Administration
Neuraminidase Inhibitors Assessment by Molecule Type
Neuraminidase Inhibitors Assessment by Stage and Molecule Type
Neuraminidase Inhibitors Therapeutics - Discontinued Products
Neuraminidase Inhibitors Therapeutics - Dormant Products
Products under Development by Companies, 2017

List of Figures
Number of Products under Development for Neuraminidase Inhibitors by Therapy Area, 2017
Number of Products under Development for Neuraminidase Inhibitors, 2017
Filed and Phase III Products, 2017
Phase II Products, 2017
Phase I and IND Filed Products, 2017
Discovery and Pre-Clinical Stage Products, 2017
Neuraminidase Inhibitors Assessment by Monotherapy Products
Neuraminidase Inhibitors Assessment by Combination Products
Neuraminidase Inhibitors Assessment by Route of Administration
Neuraminidase Inhibitors Assessment by Stage and Route of Administration
Neuraminidase Inhibitors Assessment by Molecule Type
Neuraminidase Inhibitors Assessment by Stage and Molecule Type
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll